Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Cheng Sohanya Roshan has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: May 15, 2026.
On the most recent filing, Cheng Sohanya Roshan is listed as EVP & Chief Commercial Officer at Karyopharm Therapeutics Inc. Inside the rolling window, Cheng Sohanya Roshan reported no open-market purchases and 3 open-market sales totaling $48K in KPTI. The largest disclosed transaction in the window is a sale of 4,604 KPTI shares on Mar 2, 2026, worth $43K.
Companies traded
Other insiders at KPTI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$48K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Cheng Sohanya Roshan made?
Cheng Sohanya Roshan has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Cheng Sohanya Roshan trade?
Cheng Sohanya Roshan has filed SEC Form 4 disclosures for 1 company, including KPTI.
When was Cheng Sohanya Roshan's most recent SEC Form 4 filing?
Cheng Sohanya Roshan's most recent SEC Form 4 filing on Tracefour is dated May 15, 2026.
What is Cheng Sohanya Roshan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Cheng Sohanya Roshan is listed as EVP & Chief Commercial Officer.
What is Cheng Sohanya Roshan's total buy and sell value in the current window?
Inside the rolling retention window, Cheng Sohanya Roshan bought $0 and sold $48K based on SEC Form 4 filings.
What was Cheng Sohanya Roshan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,604 KPTI shares on 2026-03-02, worth $43K, per SEC Form 4 filings.